---
title: "AHK-Cu"
canonical_url: https://peptidelibrary.app/library/ahk-cu
description: "Alanine-histidine-lysine copper complex used in hair- and skin-cosmetic research, related to GHK-Cu. Not an FDA-approved drug."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# AHK-Cu

AHK-Cu (also called Copper AHK or Ala-His-Lys copper) is a copper tripeptide. AHK-Cu is the copper complex of the tripeptide alanyl-histidyl-lysine, closely related to GHK but with alanine replacing glycine at the first position. Like GHK it binds copper(II) through the histidine imidazole and the terminal amine, and the complex rather than the free peptide is considered the active form.

Alanine-histidine-lysine copper complex used in hair- and skin-cosmetic research, related to GHK-Cu. Not an FDA-approved drug.

Also known as: Copper AHK, Ala-His-Lys copper.

Categories: Cosmetic, Experimental.

## Classification

- Type: Copper tripeptide / cosmetic research
- Mechanism class: Copper Peptide
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

AHK-Cu is the copper complex of the tripeptide alanyl-histidyl-lysine, closely related to GHK but with alanine replacing glycine at the first position. Like GHK it binds copper(II) through the histidine imidazole and the terminal amine, and the complex rather than the free peptide is considered the active form. Reported activity is concentrated in hair-follicle and fibroblast models, where it stimulated the elongation of human hair follicles ex vivo and the proliferation of cultured dermal papilla cells, with fewer markers of apoptosis (Pyo et al., 2007), and has been described as stimulating extracellular matrix production. The evidence base is smaller than for GHK-Cu and is predominantly in vitro and cosmetic; controlled human trials have not been published.

Targets: Copper-dependent enzymes, Dermal papilla (claimed).

Origin: Synthetic AHK–Cu(II) complex.

## Properties

- Molecular formula: C15H26CuN6O4
- Molecular weight: 417.96 g/mol
- CAS number: 682809-81-0

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 1
- Latest source: 2007

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. 2007. Preclinical: in vitro (cells or tissue). Population: Isolated human hair follicles and cultured dermal papilla cells. Longer hair follicles and more dermal papilla cell growth; a drop in cell death was not statistically significant. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/17703734/)

## Safety

Side effects: Irritation; Copper discoloration.

Risks: Cosmetic/research only.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

AHK-Cu is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Permitted
- Availability: OTC / Supplement

## Frequently asked questions

### What is AHK-Cu?

Alanine-histidine-lysine copper complex used in hair- and skin-cosmetic research, related to GHK-Cu. Not an FDA-approved drug.

### How does AHK-Cu work?

AHK-Cu is the copper complex of the tripeptide alanyl-histidyl-lysine, closely related to GHK but with alanine replacing glycine at the first position. Like GHK it binds copper(II) through the histidine imidazole and the terminal amine, and the complex rather than the free peptide is considered the active form.

### Is AHK-Cu FDA approved?

No. AHK-Cu is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### Is AHK-Cu banned in sport?

AHK-Cu is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to AHK-Cu?

Compounds most often compared with AHK-Cu include GHK-Cu (Copper Peptide), Palmitoyl Tripeptide-1, Acetyl Hexapeptide-8 and Acetyl Octapeptide-3. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [The effect of tripeptide-copper complex on human hair growth in vitro — Arch Pharm Res, 2007](https://pubmed.ncbi.nlm.nih.gov/17703734/)
- [Class-level evidence — Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application — Pharmaceutics, 2023](https://pubmed.ncbi.nlm.nih.gov/37896245/)
- [Class-level evidence — Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? — Molecules, 2025](https://pubmed.ncbi.nlm.nih.gov/39795193/)
